Zhejiang Xinguang Pharmaceutical Co Ltd (300519) — Tangible Net Worth Ratio
Zhejiang Xinguang Pharmaceutical Co Ltd (300519) has a Tangible Net Worth Ratio of 99.1% as of September 2025. This metric is calculated by deducting intangible assets (CN¥7.66 Million) from net assets (CN¥827.95 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 300519 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Zhejiang Xinguang Pharmaceutical Co Ltd Tangible Net Worth Ratio (2011–2024)
This chart shows how Zhejiang Xinguang Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 99.1%, reflecting net assets of CN¥827.95 Million with intangible assets of CN¥7.66 Million CNY. For live market cap and overall valuation, see Zhejiang Xinguang Pharmaceutical Co Ltd stock valuation.
Annual Tangible Net Worth Ratio for Zhejiang Xinguang Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Zhejiang Xinguang Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore 300519 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 99.1% | CN¥830.53 Million | CN¥7.88 Million | CN¥909.78 Million | ▲ +0.0 pp |
| 2023 | 99.0% | CN¥844.12 Million | CN¥8.17 Million | CN¥930.41 Million | ▲ +0.1 pp |
| 2022 | 98.9% | CN¥858.89 Million | CN¥9.28 Million | CN¥957.76 Million | ▲ +0.1 pp |
| 2021 | 98.8% | CN¥846.22 Million | CN¥10.41 Million | CN¥932.40 Million | ▲ +0.2 pp |
| 2020 | 98.6% | CN¥826.94 Million | CN¥11.54 Million | CN¥890.79 Million | ▲ +0.2 pp |
| 2019 | 98.4% | CN¥799.71 Million | CN¥12.68 Million | CN¥861.13 Million | ▼ -0.3 pp |
| 2018 | 98.7% | CN¥753.26 Million | CN¥9.60 Million | CN¥822.50 Million | ▲ +0.1 pp |
| 2017 | 98.6% | CN¥705.81 Million | CN¥9.83 Million | CN¥775.05 Million | ▲ +0.2 pp |
| 2016 | 98.4% | CN¥640.46 Million | CN¥10.14 Million | CN¥700.95 Million | ▲ +1.7 pp |
| 2015 | 96.7% | CN¥309.35 Million | CN¥10.24 Million | CN¥362.87 Million | ▲ +0.9 pp |
| 2014 | 95.8% | CN¥249.00 Million | CN¥10.52 Million | CN¥303.10 Million | ▲ +1.1 pp |
| 2013 | 94.6% | CN¥201.97 Million | CN¥10.81 Million | CN¥246.26 Million | ▲ +2.5 pp |
| 2012 | 92.2% | CN¥141.62 Million | CN¥11.09 Million | CN¥217.44 Million | ▲ +9.8 pp |
| 2011 | 82.4% | CN¥104.32 Million | CN¥18.40 Million | CN¥219.35 Million | — |